TaMoVac II: HIV vaccine trial capacity building in Tanzania and Mozambique by continued exploration of optimal DNA priming and MVA boosting strategies
Exploring new strategies for needle free vaccination
What is this study about?
It is estimated that over 33 million people are living with HIV around the world. There is currently no cure and although there are drugs available that can manage HIV, the majority of infected people are unable to access treatment. In 2009 it was estimated that 2.7 million people became newly-infected worldwide.
Therefore, developing a vaccine is a main priority in HIV research and although many options have been explored, an effective vaccine has yet to be developed.
Previous studies have shown that using an electric current instead of a needle to administer a vaccine can be more efficient.
This study will be using this method to administer a DNA plasmid vaccine which has already been tested using more conventional methods. It will assess whether the method is safe and also whether this route gives rise to a better immune response against HIV.
Who is included?
240 healthy, HIV uninfected adults, comprising 100 each from two sites in Tanzania (100 each from Mbeya and Dar es Salaam) and 40 from Maputo.
When is it taking place?
Recruitment will start in 2011.
Where is it taking place?
Tanzania (Mbeya, Dar es Salaam), and Mozambique (Maputo).
Who is funding the study?
EDCTP
Contact details
enquiries@ctu.mrc.ac.uk
Further Information
| Type of study: | Randomised trial |
| Status: | In Design |
| Study start date: | 2009 |
| Study end date: | 2014 |
| Sponsor: | Karolinska Institute, Sweden. |
| Inclusion criteria: | a. Age: 18 to 40 years |
Back to the top of page
